Protein S-palmitoylation is a widespread and dynamic post-translational modification that regulates protein-membrane interactions, protein-protein interactions, and protein stability. A large family of palmitoyl acyl transferases, termed the DHHC family due to the presence of a common catalytic motif, catalyzes S-palmitoylation; the role of these enzymes in cancer is largely unexplored. In this study, an RNAi-based screen targeting all 23 members of the DHHC family was conducted to examine the effects on the growth in non-small cell cancer (NSCLC). Interestingly, siRNAs directed against DHHC5 broadly inhibited the growth of multiple NSCLC lines but not normal human bronchial epithelial cell (HBEC) lines. Silencing of DHHC5 by lentivirus-mediated expression of DHHC5 shRNAs dramatically reduced in vitro cell proliferation, colony formation and cell invasion in a subset of cell lines that were examined in further detail. The phenotypes were restored by transfection of a wild-type DHHC5 plasmid but not by a plasmid expressing a catalytically inactive DHHC5. Tumor xenograft formation was severely inhibited by DHHC5 knockdown and rescued by DHHC5 expression, using both a conventional and tetracycline-inducible shRNA. These data indicate that DHHC5 has oncogenic capacity and contributes to tumor formation in NSCLC; thus representing a potential novel therapeutic target.
Introduction
Protein palmitoylation is increasingly understood as a common post-translational modification of widespread regulatory significance (1) (2) (3) . Dynamic cycles of palmitoylation and depalmitoylation control protein-protein interactions, proteinmembrane interactions and protein stability (4) (5) (6) (7) , and complex reciprocal palmitoylation and phosphorylation events within proteins has been recognized (8, 9) . Palmitoylation of intracellular proteins on cysteine residues (or more generally, protein S-fatty acylation) is carried out by members of a family of protein S-acyltransferases (PATs) that share a common motif, aspartic acid-histidine-histidine-cysteine (DHHC), with 23 family members encoded in the human genome (10, 11) . The founding member of the mammalian PATs, DHHC9, palmitoylates N-and H-Ras, a modification that is required for membrane association of these oncogenic proteins (12) (13) (14) (15) . Several other DHHC family members are transforming and have recently been implicated in cancers (16) (17) (18) .
NSCLC is a complex and remarkably heterogeneous disease marked by a unique natural history and molecular evolution in each patient, providing opportunities for development of targeted therapies (19) (20) (21) . Mutations in signaling receptors that act at the plasma membrane as receptor tyrosine kinases include members of the ErbB family (including the EGF receptor) and other tyrosine kinases such as ALK, LTK, ROS, RET, FLT3, EPH, IGF-1R, DDR and MET (22, 23) . These mutations activate signaling pathways, largely the Ras/Raf-MEK/ERK or PI-3K/AKT/mTOR, Src, or JAK/STAT3 pathways. As a number of signaling proteins in these pathways are palmitoylated in addition to being phosphorylated, we wondered whether DHHC family members might contribute to the growth of NSCLC. Published data from an initial genome-wide siRNA screen (24) led us to perform a secondary screen using pooled siRNAs corresponding to 23 mammalian PATs for a larger number of NSCLC and HBEC lines. In the current paper, we demonstrate that a subset of NSCLC cell lines is highly dependent on DHHC5 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 8, 2015; DOI: 10.1158/1541-7786.MCR- shRNA stable expression in lung cancer lines and HBECs pGIPZ lentiviral vectors containing a GFP reporter gene and shRNA sequences specific for DHHC5 were purchased from Open Biosystems (V2LHS_211792 and V3LHS_403115). A non-silencing shRNA (control) was also used (RHS4346). These lentiviral vectors are referred to as pGIPZ-shDHHC5-1, pGIPZ-shDHHC5-2, and pGIPZshCON, respectively. Two different shRNAs targeting DHHC5 were used, designated shDHHC5-1 (AGATCATTTTTAAACCAGA) (shDHHC5-1, corresponding to sequences derived from the 3'UTR of DHHC5) and shDHHC5-2 (CGATCGATGTCTTACAGCA).
HEK293T cells were used for lentivirus preparation by transiently transfecting with packaging, envelope, and shRNA transfer vectors using Fugene6 (Roche) (28) . h after transfection, the medium containing the lentivirus was collected and used for the transduction of lung cancer cells with the addition of 8 µg/mL of polybrene (SigmaAldrich). Stable shRNA-expressing NSCLC cell lines were generated after 10-14 days in culture in puromycin (Sigma-Aldrich). After puromycin selection, DHHC5 expression level was then assessed by immunoblotting of pooled surviving colonies. Three cells lines (H460, H650 and HCC4017) showed a high degree of DHHC5 knockdown (>90%) and were used directly in subsequent experiments. The remaining cell lines were subjected to further monoclonal selection. Colonies with lowest DHHC5 expression (normalized to HSP90) were used for further experiments.
For the production of DHHC5 knockdown HBECs, cells were transduced with the pGIPZ-shDHHC5-1 and pGIPZ-shCON and selected based on GFP fluorescence, as the HBEC cell lines used in the current study are puromycin resistant owing to the presence of vector sequences used to immortalize the cells (26) . GFP sorting was performed on a Cytomation MoFlo flow cytometer (Beckman Coulter), and carried out with a 488 nm argon ion laser. The GFP fluorescence was measured using a band pass filter at 530/20 nm. We collected the top 25% GFP-positive cells for further experiments. As >90% knockdown was achieved, no further selection was performed.
Tetracycline-inducible ("Tet-On") pTRIPZ lentiviral vectors (Open Biosystems) were used to establish inducible stable cell lines in H1299. The pTRIPZ vector contains a tetracycline response element (TRE), which drives the expression of a TurboRFP reporter in addition to the shRNA construct. The negative control pTRIPZ non-silencing vector was purchased from Open Biosystems (RHS4743), while the shRNA construct of DHHC5 shDHHC5-1 was moved from pGIPZ vector to pTRIPZ on a 345-bp XhoI/MluI DNA fragment to generate the DHHC5 targeting vector. This vector is designated pTRIPZ-shDHHC5-1. The lentiviruses were prepared similarly as for non-tetracycline inducible vectors as above, and stable inducible shRNA-expressing H1299 cell lines were created after two weeks of puromycin selection (1.25 μg/ml). Doxycycline (SigmaAldrich, 1 μg/ml) was used to induce TurboRFP/shRNA expression, which reached full intensity by 72 hours, while TurboRFP/shRNA expression could also be turned off by withdrawal of doxycycline for approximately 72 h.
Cell proliferation assays (MTS assays)
Cell proliferation was determined using the CellTiter 96 AQ ueous Non-Radioactive Cell Proliferation Assay kit (Promega) according to the manufacturer's instructions. Cells were plated onto a 96-well plate at a density of 1x10 3 
Colony formation assays
To evaluate anchorage-dependent colony formation, 500 cells were suspended in 2-3 ml of RPMI 1640 medium with 5% FBS and plated in a 6-well plate to grow for [1] [2] [3] weeks. The cells then were fixed and stained with 1 ml of 0.05% crystal violet (SigmaAldrich) to count the colonies using scanned images with ChemiDoc MP System (BioRad). The experiments were performed in triplicate wells and repeated three times.
Cell invasion assays
In vitro cell invasion assays were performed using a BD BioCoat TM Matrigel TM Invasion Chamber (BD Biosciences) containing inserts with an 8-micron pore size PET membrane, which is pre-coated with a thin layer of growth factor-reduced matrigel. The upper chamber was seeded with 2.5 x 10 4 cells suspended in 0.5 ml of serum-free RPMI 1640 medium, and the lower chamber contained 0.75 ml of RPMI 1640 medium with 5%
FBS. After 18-24 h incubation at 37ºC in a humidified atmosphere with 5% CO 2 , noninvasive cells on the upper surface of the membrane were wiped off and membranes were fixed with 100% methanol and stained with 1x Giemsa staining solution (SigmaAldrich) at room temperature for 1 h. The membranes were then photographed and the total migrating cells were counted.
Reverse transfection in H1299 with siRNAs targeting DHHC5
Two siRNAs with the same targeting sequences as the shDHHC5-1 and shDHHC5-2 were synthesized by Sigma Aldrich, designated siDHHC5-1 and siDHHC5-2.
Accordingly, two siRNAs with mismatches (bases 9 through 11 of the siRNA are replaced with their complement, referred to us the "C911 control") were used as controls for off-target effects and were designated siDHHC5-1M and siDHHC5-2M (29) .
Transient knockdown of DHHC5 with these siRNAs in H1299 were carried out using Lipofectamine RNAiMax (Life technologies) together with negative control (scramble, Sigma) and positive control (PLK1 siRNA, Sigma) according to the manufacturer's 9 instructions. The cells were then cultured for less than 72 hours at 37 °C in 5% CO 2 , followed by cell counting.
DHHC5 plasmid rescue in DHHC5 knockdown lung cancer lines
To rescue the expression of DHHC5 and its catalytically inactive mutant (designated DHHS) in the knockdown cell lines, two plasmids, pCI-neo-Flag-DHHC5 and pCI-neo-Flag-DHHS, were used. A full-length mouse DHHC5 cDNA and its mutant were subcloned to a modified pCI-neo mammalian expression vector (Promega) from pEF-BOS-HA-DHHC5 (30) and pEF-BOS-HA-mDHHCS (C134S) (31) . Plasmids were transfected into H1299, H2009 and H358 stable DHHC5-knockdown cells containing shDHHC5-1. (As the silencing sequence is derived from the 3'UTR of DHHC5 in these cells, the rescue plasmid is not subject to silencing). Transfections were performed using Lipofectamine 2000 (Life Technologies) followed by selection with G418 (250 μg/mL) for 4 weeks.
In vivo tumor formation assays
To establish tumor xenografts, cells (1 X 10 6 ) were suspended in 100 µl PBS and injected subcutaneously using a 25-gauge needle into the right flank of 6-8 week-old nonobese diabetic/severe combined immunodeficient (NOD/SCID) female mice.
Subcutaneous tumor growth was monitored by caliper measurements of tumor volume using the formula: volume = width x (length) 2 x π /6 (28). A tumor growth curve was constructed for each experiment and the data were presented as mean ± SD. Animals were sacrificed when the tumor reached 1000-1500 mm 3 , after which tumors were dissected and frozen in liquid nitrogen or fixed in 10% neutral buffered formalin for further analysis. protein were subjected to SDS-PAGE on a 6% or 8% gel, and then transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked in 5% milk, and then incubated in PBST buffer with primary antibodies at 4°C overnight, followed by incubation with horseradish peroxidase-conjugated secondary antibody (1:5000, Thermo Fisher Scientific) for one hour at room temperature. Membranes were exposed to HyBlot CL film at room temperature. Primary antibodies used were anti-DHHC5 (HPA014670, Sigma-Aldrich), anti-GAPDH (GT239, GeneTex), anti-HSP90 (SC-13119, Santa Cruz Biotechnology).
Statistical analyses
Student's t test (two-tailed) was used to determine the significance of the in vitro cell proliferation, liquid colony formation, and cell invasion data between different groups.
The significance of tumor size in vivo was determined using the two-way ANOVA test for overall significance among different treatment groups. The Gehan-Breslow-Wilcoxon test was used to analyze human survival data.
Study approval
All animal experiments were approved by the University of Texas Southwestern Medical Center Institutional Animal Care and Research Advisory Committee.
Results

Pooled siRNAs directed against DHHC5 inhibit growth over a panel of NSCLC lines
A panel of 53 NSCLC lines and 5 HBECs were reverse-transfected with pools of 4 siRNAs corresponding to all 23 human DHHC family members (Fig. S1 ). Pooled siRNAs directed only against DHHC5 were broadly suppressive over the NSCLC lines and therefore DHHC5 was chosen for validation and further study.
DHHC5 is overexpressed in NSCLC cell lines and in HBECs transformed to malignancy
Eleven NSCLC cell lines representing major subtypes (adenocarcinoma, large cell neuroendocrine and squamous cell carcinoma) were chosen; data concerning the mutational status of these cell lines is presented in Table S1 . Immunoblotting of cell lysates using an anti-DHHC5 antibody ( 
DHHC5 protein expression in human lung cancers and lack of correlation with survival
A lung tumor tissue microarray representing 218 lung cancer specimens was subjected to immunostaining using the anti-DHHC5 antibody. Data for 194 evaluable cases is presented in Fig. 1D and 1E and in Table S2 . As DHHC5 has been reported to be primarily localized to the plasma membrane (33) , and owing to variably observed high background cytoplasmic staining, only membrane staining was scored. Multiple tumor cores from each patient scored for high, moderate, or low staining (3=high, 2=moderate, 1=low, 0= none; average values expressed on a scale of 0-300) by a pathologist (Table   S2) . A continuum of DHHC5 staining was observed (Fig. 1E) . About 10% of adenocarcinomas were negative for DHHC5, with the remainder and all squamous carcinomas displaying variable staining.
When the top and bottom quartiles of DHHC5 expression were compared with respect to survival of patients from time of diagnosis, no significant difference in overall survival was noted (Fig. 1F) .
DHHC5 depletion suppresses cell proliferation and colony formation of some NSCLC cell lines but not HBECs
To investigate whether endogenous DHHC5 plays a role in the growth of NSCLC cells, we employed a lentivirus-mediated shRNA (shDHHC5-1) to stably knock down the expression of DHHC5 in eleven NSCLC cell lines as well as three HBEC lines.
DHHC5 depletion resulted in varying degrees of reduction in anchorage-dependent liquid colony formation in the 11 tested NSCLC cell lines whereas there was no effect in change observed in the HBECs (Fig. 2B) . The degree of silencing of DHHC5 expression was assessed by immunoblotting in each cell line and was judged to be greater than 90% (Fig. 2C and data not shown) .
To investigate the possibility of off-target effects in the phenotypes observed, a second shRNA targeting DHHC5 (shDHHC5-2) was used to stably knockdown DHHC5 in H1299 cells. The stable cell lines generated from shDHHC5-2 showed virtually the same results as shDHHC5-1 (Fig. 3A) . Loss of DHHC5 led to significantly reduced cellular proliferation, liquid colony formation and cell invasion. As a further control, two "C911" control siRNAs corresponding to the sequences in shDHHC5-1 and -2 were used in transient knockdowns of DHHC5 in H1299 (Fig. 3B) . C911 control siRNA bear mutations in bases 9 through 11 of the siRNA in which nucleotides are replaced with their complement. C911 control siRNAs show greatly improved performance in distinguishing on-target from off-target effects (29) . Immunoblots confirmed the efficient knockdown of DHHC5 by siDHHC5-1 and siDHHC5-2, but not the C911 controls (Fig.   3B ). Three days after the reverse transfection, cell proliferation was reduced by about 50% in cells transfected with wild type siRNAs, whereas those transfected with C911 mutant siRNAs gave similar results as the negative controls (Fig. 3B) . These results suggest that the cell growth suppression phenotype is likely related to an on-target effect directed at DHHC5. (Fig. 4, left panels) . Rescue of the cell growth and liquid colony formation by wild-type DHHC5 (but not the DHHS mutant) in DHHC5-knockdown cells was demonstrated (Fig. 4, right panels) . The catalytic activity of DHHC5 is likely to be responsible for rescue of the phenotype, as the mutation had no effect on the cellular localization of DHHC5 (Fig. S2) .
Cell migration and invasion are important processes in cancer progression. To assess the effect of DHHC5 on cell invasion, assays using matrigel invasion chambers were performed. In H1299 and H2009 cells, the knockdown of DHHC5 dramatically suppressed invasion, whereas restoration of DHHC5 totally restored the cell invasion (Fig. 5) . As H358 cells were poorly invasive in this assay, the contribution of DHHC5 was not assessed.
The effect of DHHC5 knockdown on anchorage-independent (soft agar) colony formation of H1299 cells was also assessed (Fig. S3A) . Consistent with the anchoragedependent colony formation results, suppression of DHHC5 reduced both the colony number and colony size in soft agar compared with the control cells, and re-expression of DHHC5 was able to rescue this phenotype. Several cell lines that were not sensitive to DHHC5 knockdown in terms of growth suppression (H460, H650 and HCC4017) were also examined and shown to be insensitive with respect to anchorage-independent colony formation as well (Fig. S3B) .
We examined the correlation between the DHHC5 protein expression data (Fig.   1A ) and colony formation and cell proliferation data ( Fig. 2A and B) 
DHHC5 knockdown suppresses tumor xenograft formation and growth
H1299 and H358 DHHC5 knockdown and control cells were injected subcutaneously into the flanks of NOD/SCID mice and tumor volume was measured over a 7-to 8-week period. Significantly, suppression of DHHC5 led to virtual absence (H1299) or severe suppression (H358) of tumor xenograft formation (Fig. 6) . Consistent with the data showing rescue of liquid colony, cell proliferation and soft agar formation by DHHC5, tumor xenograft formation was also rescued by DHHC5 in H1299 cells. (H358 was not tested). Tumors were examined at the time of sacrifice and confirmed to have pathology typical of lung carcinomas. Immunostaining for DHHC5 consistently showed expected membrane staining in both control and DHHC5 "rescued" tumors ( Fig. S4 ) and lack of DHHC5 staining was confirmed in the small tumors arising from DHHC5 knockdown H358 xenografts (Fig. S5) .
Tetracycline-inducible suppression of DHHC5 inhibits growth of cell lines and xenografts
To begin to address questions concerning the temporal nature of the requirement for DHHC5 in tumor formation, we developed an inducible shRNA to deplete the expression of DHHC5 in H1299 cells. A tet-on-based regulated expression system was used, which expresses both tet repressor (tet-R) and the shDHHC5-1 upon induction by doxycycline. As a first step, inducible stable cell lines that expressed either shDHHC5-1 or a control shRNA were generated in H1299 cells. The DHHC5 knockdown was reversible and time dependent, with the maximal protein depletion detected 3 days post induction. DHHC5 protein was restored 3 days after doxycycline withdrawal ( 7A). On doxycycline addition, shDHHC5-infected cells showed reduced clonogenicity as well as cell proliferation, whereas cells bearing a control shRNA showed no effect ( Fig.   7B and 7C) . With doxycycline withdrawal, the colony formation of the knockdown cells recovered to baseline (Fig. 7B) . Doxycycline-inducible DHHC5 suppression in H1299 cells also eliminated their ability to form tumors in vivo similar to the non-inducible model as described above (Fig. 7D ).
In the next set of experiments, all mice were injected with H1299 cells bearing the tet-inducible shDHHC5-1. Mice were randomized to receive either vehicle or doxycycline in the drinking water, either early (from the time of cell injection) or after tumors were established. Fully blinded assessments were carried out. As expected, sizeable tumors developed by day 56 in vehicle-treated mice in which DHHC5 was not suppressed (Fig. 7E, left panel) (Fig. 7E, center panel) , whereas doxycycline treated tumors (DHHC5 suppressed) stopped growing but did not regress. The effect of release from doxycycline was also tested (Fig. 7E, right panel) . For mice receiving doxycycline from day 0, mice were randomized on day 59 to receive either continued doxycycline or vehicle (to release from DHHC5 suppression). In this case, a slight increase in tumor growth was seen, but the rate of growth was much less as compared to previously untreated cells. These results suggest that the effects of DHHC5 suppression may persist for some time after release from suppression and that the effects of DHHC5 may be directed toward a longer-lived cell population. 
Discussion
The current study has shown that the protein palmitoyltransferase DHHC5 contributes to the proliferation, anchorage-dependent and -independent colony formation of NSCLC lines and is required for the establishment of tumor xenografts in mice for a subset of NSCLC cell lines. The enzyme is not required for growth of HBECs, which express only low levels of the enzyme. The catalytic activity of DHHC5 is implicated, because anchorage-dependent NSCLC growth suppressed by DHHC5 knockdown was rescued by DHHC5 but not by a catalytically inactive mutant. These results suggest that inhibiting DHHC5 may be a strategy for the treating a subset of NSCLCs.
Agents that target another protein lipid modification, the farnesyltransferase inhibitors (FTIs), have had limited success in cancer clinical trials (reviewed in (35)). It was previously shown (31, 36) that genetically-engineered mice bearing a hypomorphic allele of DHHC5 (5-7% of wild type level) are phenotypically normal except for a defect in learning and memory (36) . Therefore, it could be argued that specific inhibitors of DHHC5 may not display serious toxicity outside of the central nervous system. It should be noted, however, that embryonic lethality was noted in the DHHC5 knockdown mice, which were born at only 50% of the expected rate, so reproductive toxicity of targeted inhibitors may be anticipated. 
How DHHC5 contributes to the formation of tumors is probably complex. While we did not see a strong correlation between DHHC5 protein and sensitivity to DHHC5 knockdown among the 11 cancer cell lines examined, a larger sample set may be required to conclusively examine this relationship. With more data we may also be able to correlate sensitivity of DHHC5 knockdown to molecular signatures of lung cancer subtypes (24) . This may be important for developing predictive biomarkers of DHHC5 response. DHHC5 is localized to the plasma membrane in association with detergentresistant microdomains (31, 37, 38) , and as the catalytic activity is implicated, the mechanism for tumor dependence on DHHC5 for growth is likely to depend on palmitoylation of one or more substrates in these domains. Only a few substrates of DHHC5 are known. Flotillin-2 is a substrate of DHHC5 in neuronal stem cells (31) (44) . Unfortunately, our sample did not include a lung cancer with amplification in this region.
Other DHHC family members have been reported to contribute to oncogenesis in certain cell types and could also represent therapeutic targets, either alone or in combination of inhibitors of DHHC5. DHHC8, a PAT that shares approximately 50% homology at the amino acid level to DHHC5, was recently identified as a radiation susceptibility gene. DHHC8 depletion enhanced the therapeutic efficacy of X-irradiation in a mesothelioma model (45) . DHHC8 is present in the Golgi apparatus and/or endoplasmic reticulum (ER) (33) and shares some common substrates with DHHC5 (37, 41) . Interestingly, we saw that a number of NSCLC lines were sensitive to DHHC8 siRNAs ( Fig. S1 ), although these results remain to be validated. Other DHHC family members implicated in cancer include DHHC7 and DHHC21, which are PATs for sex steroid receptors (estrogen, progesterone and androgen), relevant to breast and prostate cancer (46) . In addition, DHHC17 (also known as HIP14) (18) and DHHC20 (17) transform mammalian cells, and DHHC14 is activated via a translocation in acute biphenotypic leukemia (16) .
In the future, profiling of palmitoylated proteins using some of the cell lines generated in the current study will provide a list of candidate substrates and define pathway(s) responsible for dependence on DHHC5 for cell growth. This will be a major undertaking, as a previous study suggests the number of substrates is potentially quite large (31) . However, it may not be necessary to identify the relevant substrates of DHHC5 to develop inhibitors. For example, protein kinase inhibitors were initially developed using assays that track inhibition of phosphorylation of artificial substrates or autophosphorylation of the kinase even before relevant substrates were known (see (47) (48) (49) and references therein). Autopalmitoylation is currently is being used in a screening assay for DHHC enzyme inhibitor development (50) . ) from H1299 control, DHHC5 knockdown and rescued lines were injected on day 0 and tumor dimensions were assessed twice weekly using digital calipers (N=4 for control group, N=5 for knockdown and N=4 for rescue group). B, H358 control and knockdown cells (1 X 10 6 ) were injected subcutaneously into NOD/SCID mice and tumor growth was monitored weekly (N=5). 
